What is Elamipretide?
Elamipretide targets mitochondrial biology. Its approved product, Forzinity, has a specific Barth syndrome indication rather than a general anti-aging use.
Biological role or research focus
Mitochondrial-targeted peptide.
Forzinity has a specific Barth syndrome indication; this is not approval for general longevity use.
Names you may encounter
SS-31 · SS31 · Forzinity
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Mitochondrial-targeted tetrapeptide
- Main research area
- Barth syndrome
- Evidence featured
- Human crossover trial + open extension
- Source check
- October 4, 2026
Quick answers
- Is Elamipretide FDA approved?
- Yes. Forzinity (NDA 215244, accelerated approval September 19, 2025) to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. Source ↗
- Is Elamipretide safe?
- Recently approved mitochondria-targeting drug for Barth syndrome; human safety data are very limited, and injection-site and allergic reactions are the main concerns. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Elamipretide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Elamipretide?
- Yes. Our records list 2 FDA actions naming it, most recently on August 24, 2026: FDA warning letter to a "research peptide" seller (Peak Performance Peptides) naming "SS-31" (elamipretide), "PT-141", tesamorelin and GLP-1 products as unapproved new drugs. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| TAZPOWER (2021) | Human crossover trial + open extension | 12 participants with Barth syndrome in the blinded phase. |
| SS-31 · inflammatory memory model (2019) | Animal study | Mice with lipopolysaccharide-induced inflammation and memory impairment. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human crossover trial + open extension · 2021
TAZPOWER
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
- Population / model
- 12 participants with Barth syndrome in the blinded phase.
- Study design
- 12-week crossover periods with washout, then an open-label extension.
- Main finding
- Neither primary endpoint—six-minute walking distance or symptom score—was met in the blinded phase. Improvements appeared in the extension, with eight participants reaching 36 weeks.
- Limits & context
- An uncontrolled extension is less reliable for attributing benefit. Read the later FDA decision separately: accelerated approval used knee-muscle strength and requires confirmation of clinical benefit.
Animal study · 2019
SS-31 · inflammatory memory model
What does the mouse cognition experiment establish?
- Population / model
- Mice with lipopolysaccharide-induced inflammation and memory impairment.
- Study design
- Behavioral testing plus hippocampal mitochondrial, inflammatory, cell-death, and synaptic measurements.
- Main finding
- Elamipretide improved the tested learning and memory outcomes alongside mitochondrial and synaptic measures.
- How to read it
- Improvement after experimentally induced inflammation is distinct from preventing dementia or improving normal human memory.
- Limits & context
- The abstract does not provide group sizes or numerical treatment effects. Animal findings cannot establish perioperative cognitive benefit or safety in humans.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
20 registered studies name Elamipretide as an intervention; 3 are recruiting or under way, 1 has not started recruiting yet, 13 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 20 listed studies.
Further reading · 3 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. ↗
Sports medicine (Auckland, N.Z.) · 2026 Aug · Journal Article, Review
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. ↗
International journal of molecular sciences · 2025 Jan 23 · Journal Article, Review
Read available full text ↗
Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD). ↗
Cells · 2021 Sep 19 · Journal Article, Review
Read available full text ↗
Risks & interactions
Recently approved mitochondria-targeting drug for Barth syndrome; human safety data are very limited, and injection-site and allergic reactions are the main concerns.
Label safety data come from only 12 males with Barth syndrome in a small crossover trial and open-label extension, so rare or long-term risks are not well understood. The label has no drug interaction section.
No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
- People with a serious allergic reaction to elamipretide or any ingredient
- Newborns: the product contains benzyl alcohol and is not approved for neonates
Serious risks
- Allergic reactions, from skin rashes and cough to serious reactions needing emergency care, appearing minutes to months after starting
- Benzyl alcohol toxicity (gasping syndrome) in newborns
Common side effects
- injection-site reactions
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Forzinity (elamipretide) prescribing information ↗
Safety evidence & remaining uncertainty
Injection-site reactions were common in the development program, and serious reactions have been reported. Approval in a rare mitochondrial disorder does not establish a favorable benefit-risk balance for healthy people.
Source: FDA · First treatment for Barth syndrome ↗
Regulatory status
- U.S. FDA approval
- Approved
Forzinity (NDA 215244, accelerated approval September 19, 2025) to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. It has FDA approval (2025), so S0 does not apply. source
FDA actions
- FDA warning letter to a "research peptide" seller (Peak Performance Peptides) naming "SS-31" (elamipretide), "PT-141", tesamorelin and GLP-1 products as unapproved new drugs. (2026-08-24) source
- FDA warning letter to a "research peptide" seller (Royal Peptides) naming "SS-31 (Elamipretide)", tesamorelin, PT-141 and GLP-1 products as unapproved new drugs. (2026-08-24) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
FDA granted accelerated approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. Improved knee-extensor strength supported that decision; a confirmatory trial is required to establish the predicted clinical benefit.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It interacts with cardiolipin in the inner mitochondrial membrane. Barth syndrome disrupts cardiolipin biology, providing the disease-specific rationale for studying this pathway.
Molecular structure
Questions worth asking
- Is the discussion about Forzinity or a different product?
- Does the claim match the specific population studied?
- Forzinity has a specific Barth syndrome indication; this is not approval for general longevity use.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does accelerated approval mean every benefit is confirmed?
No. It can rely on a measure reasonably likely to predict benefit, with further confirmation required.
Why show a trial that missed its primary endpoints?
It is part of the evidence history. The blinded phase and uncontrolled extension need separate interpretation.
References & editorial record
- FDA · First treatment for Barth syndrome ↗
- A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗
- Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Mitochondrial peptides: what MOTS-c, humanin and SS-31 (elamipretide) actually show in people
MOTS-c and humanin are made by mitochondria; elamipretide (SS-31) is a drug aimed at them. Mouse data and blood-level studies back the first two; only elamipretide has human trials and a narrow FDA approval.
Read the guide →
